NAD+observational1980

NAD+-dependent 15-hgydroxyprostaglandin dehydrogenase from porcine kidney. II. Kinetic studies.

Biochimica et biophysica acta

confidence

Key findings

Kinetic mechanism study of porcine renal NAD+-dependent 15-hydroxyprostaglandin dehydrogenase; no clinical or biological endpoints reported.

View source on PubMed (PMID 7190439) ↗

Sample size
N/A
Population
In vitro enzyme kinetics study (porcine renal NAD+-dependent 15-hydroxyprostaglandin dehydrogenase)
Dosing
N/A
Duration
N/A
Route
N/A
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

The kinetic mechanism of porcine renal NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (11 alpha, 15-dihydroxy-9-oxoprost-13-enoate:NAD+ 15-oxidoreductase, EC 1.1.1.141) was investigated. Initial velocity studies gave intersecting double reciprocal plots that conform to a sequential mechanism. Product inhibition studies indicated that 15-keto-prostaglandin E2 exhibited linear non-competitive inhibtion with respect to either prostaglandin E2 or NAD+, and NADH yielded linear competitive inhibition with respect to NAD+. Dead-end inhibition studies showed that adenosine-5'-diphosphoribose inhibited the enzyme competitively with respect to NAD+ as expected, but inhibited the enzyme non-competitively with respect to prostaglandin, E2. Alternate substrate studies indicated that a mixture of 3-acetyl-NAD+ and NAD+ gave a concave upward double reciprocal plot, while a mixture of prostaglandin E2 and prostaglandin F2 alpha yielded a linear plot. These results are consistent with an ordered Bi-Bi mechanism where NAD+ is added first, followed by prostaglandin E2, and 15-keto-prostaglandin E2 is released, followed by NADH.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.